List of health departments and ministries

Exact Sciences receives regulatory approval for the Oncotype DX Breast Recurrence Score® Program in Japan

Retrieved on: 
Lundi, août 16, 2021
Biology, Breast cancer, Colon, Epic Sciences, Electric Bond and Share Company v. Securities and Exchange Commission, Recurrence, Program, Lymph, Exact Sciences (company), MCRPC, CEO, News, Risk, Genomic Health, Ministry, Collaborative Group on Hormonal Factors in Breast Cancer, Breast cancer classification, Research, Annual report, Security (finance), Patient, Genomics, List of health departments and ministries, Growth, Software, Breast, Neoplasm, Exact sciences, Cancer, DCIS, Nasdaq, Woman, MHLW, Prostate cancer, Dietary supplement, Medical imaging

Breast cancer is the most common cancer in Japanese women, and more than 90,000 new breast cancer cases were diagnosed in Japan in 2020.i The Oncotype DX Breast Recurrence Score Program approved in Japan combines the Oncotype DX Breast Recurrence Score test and software developed for the Japanese market.

Key Points: 
  • Breast cancer is the most common cancer in Japanese women, and more than 90,000 new breast cancer cases were diagnosed in Japan in 2020.i The Oncotype DX Breast Recurrence Score Program approved in Japan combines the Oncotype DX Breast Recurrence Score test and software developed for the Japanese market.
  • "MHLW's approval of Oncotype DX is great news for breast cancer patients in Japan and reflects the powerful evidence backing the Oncotype DX test," said Kevin Conroy, chairman and CEO.
  • In breast cancer, the Oncotype DX Breast Recurrence Score test is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.
  • NOTE: Oncotype, Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype DX Breast DCIS Score, Oncotype DX Genomic Prostate Score, Oncotype MAP Pan-Cancer Tissue, and Oncotype DX AR-V7 Nucleus Detect are trademarks or registered trademarks of Genomic Health, Inc.

The Russian Direct Investment Fund: on the first anniversary of Sputnik V registration official data from leading countries confirms the vaccine's high safety and efficacy profile

Retrieved on: 
Mercredi, août 11, 2021
Myocarditis, Vaccination, Sputnik V COVID-19 vaccine, Thrombosis, Safety, Ministry of Health (Bahrain), Injection, Equity, Partnership, Immunity, Hospital, COVID-19, Russian Direct Investment Fund, CVT, Coronavirus, List of health departments and ministries, Death, Ministry, Toyota K CVT transmission, RBD, COVID, Pharmaceutical industry, Vaccine

MOSCOW, Aug. 11, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund), investor in the Russian Sputnik V vaccine against coronavirus, announces the results of its joint work with Ministries of Health and regulators of the leading countries to collect and analyze real world vaccination data on the first anniversary of the vaccine's registration confirming its high safety and efficacy profile.

Key Points: 
  • In several countries where multiple vaccines are used, the Russian vaccine has demonstrated one of the best safety and efficacy parameters.
  • To date Sputnik V has been approved in 69 countries with total population exceeding 3.7 billion people - nearly half of the global population.
  • The data confirms that Sputnik V remains protective against newly detected variants and retains one of the best safety and efficacy parameters.
  • The Russian Ministry of Health has also published data on Sputnik V's efficacy against the Delta variant.

Elo and 19Labs Partner To Offer Next Generation Telehealth Kiosks

Retrieved on: 
Jeudi, juillet 15, 2021
Articles, Health informatics, Technology, Science and technology, Telehealth, Interactive kiosk, eHealth

19Labs and Elo are working together to bring eClinics to these new locations globally.

Key Points: 
  • 19Labs and Elo are working together to bring eClinics to these new locations globally.
  • 19Labs' GALE eClinics are next generation point-of-care platforms that seamlessly integrate leading mobile and healthcare technologies into cost-effective and smart solutions such as telehealth carts, healthcare kiosks, or portable telehealth kits.
  • "19Labs' eClinics enable our customers to easily deploy enhanced telehealth using the world's most advanced diagnostic devices: from ultrasound, ECGs, and even blood pressure," said Dan Ludwick, Chief Product Officer, Elo.
  • "Elo has been a great partner," says Ram Fish, 19Labs CEO & Founder.